Insider Selling: Omada Health (NASDAQ:OMDA) CEO Sells $248,783.68 in Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 12,944 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $19.22, for a total value of $248,783.68. Following the sale, the chief executive officer directly owned 382,594 shares in the company, valued at approximately $7,353,456.68. This represents a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Omada Health Price Performance

Omada Health stock opened at $15.09 on Monday. The company has a market cap of $923.81 million, a PE ratio of 71.86 and a beta of 2.13. The company has a fifty day moving average price of $20.14 and a two-hundred day moving average price of $17.74. Omada Health, Inc. has a 12 month low of $10.28 and a 12 month high of $25.45.

Omada Health (NASDAQ:OMDA) last issued its earnings results on Thursday, November 5th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.08. Omada Health had a net margin of 4.21% and a return on equity of 5.91%. The company had revenue of $91.31 million for the quarter. Equities research analysts anticipate that Omada Health, Inc. will post 0.09 earnings per share for the current year.

Hedge Funds Weigh In On Omada Health

A number of institutional investors and hedge funds have recently bought and sold shares of OMDA. Sterling Capital Management LLC increased its position in shares of Omada Health by 1,161.6% during the 3rd quarter. Sterling Capital Management LLC now owns 1,577 shares of the company’s stock valued at $33,000 after purchasing an additional 1,452 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in shares of Omada Health in the second quarter valued at $53,000. State of Alaska Department of Revenue acquired a new stake in shares of Omada Health in the third quarter valued at $59,000. Versant Capital Management Inc lifted its holdings in shares of Omada Health by 319.3% in the second quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock valued at $66,000 after buying an additional 2,283 shares during the period. Finally, Legal & General Group Plc bought a new position in Omada Health during the second quarter valued at about $76,000.

Analyst Ratings Changes

OMDA has been the topic of a number of recent research reports. Wall Street Zen raised shares of Omada Health from a “hold” rating to a “buy” rating in a report on Sunday, October 11th. Weiss Ratings lowered Omada Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, October 8th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of Omada Health in a research report on Friday, September 11th. Zacks Research downgraded Omada Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 4th. Finally, Canaccord Genuity Group boosted their price objective on Omada Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Eleven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.33.

Omada Health News Roundup

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Omada reported Q3 revenue of $91 million, up 34% year over year, and total members grew 36% to a record 1.1 million. Net income was $7 million versus a year-ago loss, while adjusted EBITDA increased to $12 million. The company also raised its full-year 2026 financial outlook. Omada Health Reports Third Quarter 2026 Results
• Positive Sentiment: Quarterly revenue exceeded FactSet’s estimate, and reported earnings also topped consensus estimates, providing evidence of stronger-than-expected operating performance. Earnings Flash: Q3 Revenue
• Neutral Sentiment: Unusual options activity was reported after Omada’s earnings, signaling heightened trading interest but not indicating a clear direction for the stock. Unusual Options Volume Report
• Negative Sentiment: Several analysts took a more cautious stance: Wells Fargo cut its price target to $19 and maintained an “equal weight” rating, while Zacks Research downgraded OMDA from “strong buy” to “hold.” Wells Fargo analyst actions Zacks Research analyst action
• Negative Sentiment: Barclays also lowered its target from $24 to $22, although it retained an “overweight” rating. Barclays analyst action

About Omada Health

Omada Health, Inc (NASDAQ: OMDA) is a digital health company that provides virtual care programs for people managing chronic conditions. Its platform combines personalized health coaching, clinical support, behavioral-change tools and connected devices to help members monitor and improve their health.

The company’s offerings focus primarily on cardiometabolic conditions, including diabetes, prediabetes, hypertension and obesity, as well as musculoskeletal conditions. Depending on the program, members may receive access to digital lessons, health tracking, remote monitoring, care teams and clinical guidance through Omada’s technology platform.

Omada Health was founded in 2011 and serves employers, health plans and other healthcare organizations in the United States.